Windlas Biotech Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/bln72j5xsse10sorgnxlrh6o.pdf

Key Takeaways


CDMO: The Base Business

Hitesh Windlass: "When the volume growth is not very high, our customers also look for new innovative ideas. And that is where, you know, we are trying to sort of differentiate ourselves and say and bring new products with DCGI approvals with bio equivalent studies and sometimes even clinical trial studies."

Trade Generics: The Growth Bet

Hitesh Windlass: "We are looking at it as a triple A approach. Authentic products, affordable prices, and accessible medicines."

Exports: Deliberate Retreat, Long-Term Ambition

Hitesh Windlass: "From an export perspective, you should look at the full year kind of a horizon and not anything sooner because all of these will be sort of needles in the fire until it finally emerges and comes from that."

Injectable CAPEX & Capacity Expansion


Capital Allocation & Inorganic Strategy

Hitesh Windlass: "In this quarter, actually, we, in fact, conducted legal, financial and quality diligence on one asset, and we found some adverse things that, we decided not to pursue that. In fact, some of those diligence costs are also included in our this quarter's P&L."

Margins & Financial Health


Guidance & Commitments

CommitmentSpecificsTimeline
Injectable facility commercial productionMechanical completion by March 2023, then 3-4 months qualification; production startEnd Q1 to mid Q2 FY24
South Africa export revenueOne product approved, another closely following; commercialization expectedQ4 FY23
Five-year growth targets2x CDMO, 3x Trade Generics, 4x exports (from base)By 2025 end
Gross margin rangeSustain at 35-37%, potential slight increase as Trade Generics mix growsOngoing
Capacity expansion triggerBegin creating next unit when utilization reaches 50-55%When current capacity (~₹600 Cr) approaches limit
Exports long-term targetGrow to ₹75 crores (3x of original ₹25 Cr base)By 2025 end
IPO proceeds deploymentRemaining funds spent on injectable CAPEXBefore March 2023 mechanical completion

Key Metrics

MetricQ2 FY23
Revenue growth15.2% YoY
CDMO revenue₹106.6 cr, +17% YoY
Trade Generics revenue₹23.1 cr, +36.8% YoY
Exports revenue₹2.5 cr, -54.1% YoY
CDMO revenue share~80% of consolidated revenue
Trade Generics revenue share~17% of consolidated revenue
Gross margin~36% (H1 FY23), +154 bps YoY for Q2
EBITDA margin12.1%, +67 bps YoY
PAT₹12.2 cr, +47% YoY
Complex generics share~80% of product mix
Top 10 customer concentration43% of revenue, down from 45% in H1
Capacity utilization44%
Trade Generics product count~200 SKUs
IPO proceeds utilized₹100 cr, 65% of ₹153.1 cr raised
Buyback approved₹25 cr, no promoter participation